Phase Ib/II Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
Phase of Trial: Phase I/II
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs Lanreotide (Primary) ; Pembrolizumab (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms PLANET
- 31 Jul 2017 Status changed from not yet recruiting to recruiting.
- 23 May 2017 Planned End Date changed from 1 Jun 2021 to 1 Jun 2020.
- 23 May 2017 Planned initiation date changed from 1 May 2017 to 1 Jul 2017.